OV increases its share capital due to warrant exercise

Press release

Hoersholm, Denmark, Octoeber 3, 2019 – Oncology Venture A/S (“OV”) today announces that, as a consequence of an exercise of 230,000 warrants, the share capital in the company will increase by nominal DKK 11,500 and the number of shares will increase by 230,000.

The increase has been executed without any pre-emption rights for the existing shareholders of the company or others. The shares are subscribed in cash at a price of DKK 0.52 per share, of nominally DKK 0.05. Proceeds to the company are DKK 119,600. The new shares are ordinary shares without any special rights and are freely transferable and negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends. OV’s current share capital amounts to DKK 3,523,874.95 and will after registration of the capital increase be DKK 3,535,374.95. The current number of shares in the company is 70,477,499 and will after the registration of the capital increase be 70,707,499.

For further information, please contact:

Henrik Moltke, CFO
E-mail: hm@oncologyventure.com
Telephone +45 22 44 54 04

About Oncology Venture A/S
Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, DRP®. The company has a mature portfolio of seven drug candidates, including compounds in the pre-registration stage. Based on a pre-treatment biopsy, DRP® reveals the genetic fingerprint of an individual patient’s tumor and predicts the treatment response of a certain cancer drug or drug candidate. By including only patients with sensitive tumors in a clinical trial, it is possible to avoid background noise from non-sensitive patients in efficacy read-outs. Once a new drug is approved, DRP® can be used to identify just those patients who can benefit from treatment. Learn more at www.oncologyventure.com

Follow us on social media:
Facebook: https://www.facebook.com/oncologyventure/
LinkedIn: https://www.linkedin.com/company/oncology-venture/
Twitter: https://twitter.com/OncologyVenture

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Email: ca@skmg.se. Tel: +46 11 32 30 732

This information is information that Oncology Venture A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 3, 2019.

Attachment

Sign up for press releases and receive relevant information about Oncology Venture A/S

Press Contact

For any inquiries, please contact:

CFO Henrik Moltke
E-mail: Email Us
Tel. +45 53 63 96 37